Evidence mapPaperPMID 35533966Full record

ArticleAcademic pediatrics

Association Between Weight Promoting Medication Use and Weight Status Among Children and Adolescents in the United States.

Mechelle D Claridy, Numa P Perez, Kathryn S Czepiel, Nonyerem O Acholonu, Fatima Cody Stanford

Open access · greenAbstract read
In one paragraph

Article in Academic pediatrics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact, top 94% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Mechelle D ClaridyDepartment of Epidemiology and Biostatistics, University of Georgia (MD Claridy), Athens, Ga.
Numa P PerezDepartment of Surgery, Massachusetts General Hospital and Harvard Medical School (NP Perez), Boston, Mass.
Kathryn S CzepielDivision of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Stanford School of Medicine (KS Czepiel), Stanford, Calif.
Nonyerem O AcholonuDepartment of Pediatrics, Massachusetts General Hospital and Harvard Medical School (NO Acholonu), Boston, Mass.
Fatima Cody StanfordDepartment of Medicine, Neuroendocrine Unit, Department of Pediatrics, Pediatric Endocrinology, Massachusetts General Hospital and Harvard Medical School (FC Stanford), Boston, Mass. Electronic address: fstanford@mgh.harvard.edu.
Harvard University · USStanford Medicine · USUniversity of Georgia · US

Funding

ROLE OF DIETARY CONSTITUENTS ON GENE EXPRESSION IN INTESTINAL EPITHELIUMP30DK040561 · MASSACHUSETTS GENERAL HOSPITAL · 1994 to 2025
$6.0M
NIDDK NIH HHS L30 DK118710NIDDK NIH HHS P30 DK040561
6 · The paper itself

Abstract

objectivesThe objectives of this study were to 1) examine the prevalence of prescription medication use overall and 2) examine the association between weight promoting medication (WPM) use by therapeutic class and weight status among a nationally representative sample of the children and adolescents in the United States. This study also further investigated antidepressant medication use among this population.

methodsThis cross-sectional study used data from the National Health and Nutrition Examination Survey from 2013 to 2018. Children and adolescents ages 2 to 19 years were included in this study.

resultsOf the 68,057,468 derived participants (34,507,154 [50.7%] male; 33,564,059 [49.3%] aged 2-10 years; 34,905,058 [51.3%] non-Hispanic White), 14,895,618 (22.2%) used a prescription medication in the prior 30 days, 21.7% (3,235,323) of which were considered weight promoting. There was no significant difference between weight status and WPM use for overall prescription medication use. Nevertheless, for overall antidepressant medication use, those with obesity were less likely to be prescribed antidepressant WPM when compared to those with normal weight (adjusted odds ratios 0.4; 95% confidence interval 0.2-0.7).

conclusionsThese findings suggest that although there was no significant association between WPM use and weight status overall when examining the association by therapeutic class, most children with obesity were not using antidepressant WPM. This is reassuring and potentially an active attempt at avoiding the use of medications that have an exacerbating effect on weight gain. When choosing antidepressant medications, providers, parents, and patients consider the WPM effects and appropriately choose a medication best suited to the child's health status.

Indexed as

ObesityPrescription DrugsAdolescentBody Mass IndexChildCross-Sectional StudiesFemaleHumansMaleNutrition SurveysUnited StatesWeight GainPrescription Drugsobesitypediatricsweight gain

Identifiers

PMID35533966
PMCPMC10042467
OpenAlexW4229072964

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.